Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AAREYDRUGS | NSE
0.51
0.66%
Healthcare
Drug Manufacturers-Specialty & Generic
31/03/2024
05/06/2026
77.84
75.60
78.50
75.00
Aarey Drugs & Pharmaceuticals Limited engages in the manufacture and sale of active pharmaceutical ingredients intermediates and specialty chemicals for various industrial applications in India. The company provides mono methyl and die methyl urea ortho para nitro anisole 2 bromomethyl 1 and 3 dioxalane and uracile as well as active pharma ingredients such as metformin HCL mefenamic acid and doxophylline. It also offers chemicals and solvents including aeromatics chemicals chemical acids chlor alkalies glycols and glycol ethers fiber intermediates acetates and esters and chlorinated solvents as well as industrial alchols ketones amines oleochemicals intermediates olefines phosphates fertilizers monomers and chemicals. The company's pharmaceutical products are used by pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. It also trades in industrial solvents and chemicals. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai India.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
27.7%1 month
34.3%3 months
63.7%6 months
63.2%32.75
-
1.45
0.24
0.10
19.38
0.56
-
42.72M
2.25B
23.74M
-
0.56
54.10
149.10
3.74
-
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
10.69
Range1M
18.19
Range3M
45.69
Rel. volume
1.57
Price X volume
8.11M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Lyka Labs Limited | LYKALABS | Biotechnology | 63.57 | 2.27B | 5.32% | 813.94 | 86.05% |
| Brooks Laboratories Limited | BROOKS | Drug Manufacturers-Specialty & Generic | 65.68 | 1.75B | 1.23% | n/a | 8.60% |
| Alpa Laboratories Limited | ALPA | Drug Manufacturers-Specialty & Generic | 68.92 | 1.46B | 0.12% | 13.54 | 3.45% |
| Krebs Biochemicals & Industries Limited | KREBSBIO | Drug Manufacturers-Specialty & Generic | 65.01 | 1.40B | -0.81% | n/a | -162.25% |
| Bal Pharma Limited | BALPHARMA | Drug Manufacturers-Specialty & Generic | 86.23 | 1.38B | -1.01% | 25.83 | 201.53% |
| Par Drugs And Chemicals Limited | PAR | Drug Manufacturers-Specialty & Generic | 89.89 | 1.12B | 3.67% | 19.90 | 0.00% |
| Biofil Chemicals and Pharmaceuticals Limited | BIOFILCHEM | Drug Manufacturers-Specialty & Generic | 35.29 | 589.40M | 0.34% | 181.38 | 2.41% |
| Mangalam Drugs & Organics Limited | MANGALAM | Drug Manufacturers-Specialty & Generic | 28.5 | 460.91M | 0.04% | n/a | 71.03% |
| Lasa Supergenerics Limited | LASA | Drug Manufacturers-Specialty & Generic | 7.91 | 399.96M | 2.73% | n/a | 22.84% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Madhav Copper Limited | MCL | Copper | 59.6 | 1.64B | -0.28% | 82.22 | 32.14% |
| Cubex Tubings Limited | CUBEXTUB | Copper | 86.92 | 1.26B | -0.36% | 35.85 | 21.78% |
| Touchwood Entertainment Limited | TOUCHWOOD | Advertising Agencies | 70.46 | 785.54M | -2.29% | 50.06 | 4.88% |
| Sagardeep Alloys Limited | SAGARDEEP | Copper | 24.6 | 427.05M | -3.42% | 58.62 | 43.14% |
| Heads UP Ventures Limited | HEADSUP | Apparel Retail | 7.24 | 158.63M | 3.43% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 19.38 | 24.85 | Cheaper |
| Ent. to Revenue | 0.56 | 11.40 | Cheaper |
| PE Ratio | 32.75 | 51.36 | Cheaper |
| Price to Book | 1.45 | 6.83 | Cheaper |
| Dividend Yield | - | 0.52 | - |
| Std. Deviation (3M) | 63.74 | 42.17 | Riskier |
| Debt to Equity | 0.24 | 0.35 | Cheaper |
| Debt to Assets | 0.10 | 0.17 | Cheaper |
| Market Cap | 2.25B | 290.82B | Emerging |